Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,304 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Pediatric Clear all
Completed Phase 1 Interventional

Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia

NCT03964259
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL, Pediatric Lymphoma
Interventions
Intravenous fluids
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
1 Year to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 28, 2026, 6:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Multisite Implementation of COMPRENDO

NCT06055296
View directory record Official record
Conditions
Pediatric Cancer
Interventions
COMPRENDO Peer Navigation Intervention
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
4
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Early Phase 1 Interventional Results available

Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain

NCT00452868
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity
Interventions
Donepezil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
8 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 28, 2026, 6:41 PM EDT
Enrolling by invitation No phase listed Observational

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

NCT02315599
View directory record Official record
Conditions
Pediatric Cancers, Hematologic Malignancies, Solid Tumors
Interventions
anti-CD19 CAR
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2050
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Early Phase 1 Interventional

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

NCT03445858
View directory record Official record
Conditions
Childhood Solid Tumor, Childhood Lymphoma, Relapsed Cancer, Refractory Cancer, Adult Solid Tumor, Adult Lymphoma
Interventions
Pembrolizumab, Decitabine, Hypofractionated Index Site Radiation
Drug · Radiation
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months to 40 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas

NCT02415816
View directory record Official record
Conditions
Sarcoma, Bone, Sarcoma, Soft Tissue, Osteosarcoma, Sarcoma, Ewing, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft-tissue Sarcoma
Interventions
Diffusion Weighted Magnetic Resonance Imaging
Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Recruiting Phase 1 Interventional

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

NCT07698899
View directory record Official record
Conditions
Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
Interventions
25 mCi 177Lu- DTPA-omburtamab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
3 Years to 22 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional

Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease

NCT00118326
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
Interventions
filgrastim, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Expressive Storytelling to Share Adolescents/Young Adults Cancer Stories

NCT04855487
View directory record Official record
Conditions
Pediatric Cancer, Growth, Posttraumatic, Nurse-Patient Relations, Narrative Medicine
Interventions
Nurse-patient dyadic storytelling intervention
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
15 Years to 25 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 28, 2026, 6:41 PM EDT
Completed No phase listed Observational

Collecting and Storing Tissue From Young Patients With Cancer

NCT00898755
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Central Nervous System Neoplasm, Ewing Sarcoma, Germ Cell Tumor, Leukemia, Lymphoma, Malignant Neoplasm, Neuroblastoma, Osteosarcoma, Retinoblastoma, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
65
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 28, 2026, 6:41 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial

NCT07442578
View directory record Official record
Conditions
Childhood Cancer Survivors, Cardiotoxicity, Cardiovascular Diseases, Anthracycline-induced Cardiotoxicity
Interventions
HIIT Exercise Program, MICT Exercise Program
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

NCT00084838
View directory record Official record
Conditions
Central Nervous System Tumor, Pediatric
Interventions
filgrastim, cisplatin, cyclophosphamide, cytarabine, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, temozolomide, therapeutic hydrocortisone, vincristine sulfate, radiation therapy, Dactinomycin
Biological · Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 18 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
12
States / cities
Stanford, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 28, 2026, 6:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

NCT05350748
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Day to 120 Years
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2042
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

NCT06721689
View directory record Official record
Conditions
Refractory Solid Tumors, Relapsed Solid Tumors, Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Rhabdomyosarcoma, Refractory Rhabdomyosarcoma
Interventions
PEEL-224, Vincristine, Temozolomide (TMZ)
Drug
Lead sponsor
Theodore Laetsch
Other
Eligibility
1 Year to 30 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The OneFlorida Cancer Control Alliance: Implementing the 6As in Pediatric Primary Care

NCT03044691
View directory record Official record
Conditions
Smoking Cessation
Interventions
ResearchACTS software
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
11 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 28, 2026, 6:41 PM EDT
Completed No phase listed Observational

Eligibility Screening for a NCI Pediatric Oncology Branch Research Study

NCT00026780
View directory record Official record
Conditions
Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia, Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 35 Years
Enrollment
1,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 28, 2026, 6:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

NCT03301168
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Primary Immune Deficiency Disorder, Osteopetrosis, Cytopenia, Hemoglobinopathy in Children, Anemia, Aplastic
Interventions
BPX-501 T cells, Rimiducid
Biological · Drug
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
1 Month to 26 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 1 Interventional Results available

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

NCT02171260
View directory record Official record
Conditions
Pediatrics, Solid Tumors
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

NCT02625480
View directory record Official record
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
Up to 21 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Barriers and Facilitators in Access to OT/PT in Pediatric Cancer Survivors

NCT05305950
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Patient population
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors

NCT05138991
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Echocardiogram Recording, Questionnaire Administration, Stress Cardiac Magnetic Resonance Imaging, Wireless Synchronized Cardiac Function Monitoring Device
Procedure · Other · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 28, 2026, 6:41 PM EDT
Withdrawn Phase 1 Interventional

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).

NCT05134740
View directory record Official record
Conditions
Hodgkins Lymphoma, Non Hodgkins Lymphoma
Interventions
TAA-specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 28, 2026, 6:41 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors

NCT05778825
View directory record Official record
Conditions
Survivors of Childhood Cancer, Alopecia
Interventions
Oral Minoxidil, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

NCT02332889
View directory record Official record
Conditions
Gliomas, Medulloblastoma, Neuroectodermal Tumors, Primitive
Interventions
Vaccine (autologous dendritic cells), Decitabine and Hiltonol
Biological · Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 28, 2026, 6:41 PM EDT